Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer

Electronic Nose (E-nose) Technology to Assess Pathologic Response and Post- Treatment Progression for Non-small Cell Lung Cancer: a Phase II Study

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure changes in certain chemicals in the breath before and after standard neoadjuvant therapy in people with NSCLC.

Inclusion Criteria:

• Age ≥18
• Untreated clinical stage I NSCLC amenable to upfront surgery
• Untreated stage II to IIIB NSCLC amenable to neoadjuvant treatment followed by surgery
• ECOG Performance Status of ≤2 Of note, the E-nose is a completely noninvasive technology (only breath samples are collected). Therefore, this intervention would have no effects on a developing human fetus. There are therefore no requirements for the study population related to contraception or pregnancy testing.